Shanghai Seizes Cell Samples As China Tightens Biosecurity Enforcement
First Action Since 15 April Law Enactment
Authorities in China appear to be taking a tough early stance in the enforcement of a new national Biosecurity Law that took effect in mid-April, with an imported human cell shipment in Shanghai being seized.
You may also be interested in...
Nanjing Legend gains FDA approval for its BCMA cell therapy, the second to go to market in the US marks a win for true innovators from China, not cheaper but similar products, some say.
Off-label use of cancer drugs in China is legal and even common in certain cases. But a line has been crossed in cases of active promotion and even conflicts of interest for some high-priced products and unproven cell therapies, unveiled by a Chinese physician whistleblower, regulatory observers say.
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.